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ABSTRACT
Malignant Mesothelioma (MM) is a rare and aggressive form of tumour that 
affects the lining of the internal organs for which current treatments have not been 
proven to be very effective. P16INK4A tumour suppressor encoding CDKN2A gene is often 
downregulated in MM. This protein is a cyclin dependent kinase 4 and 6 inhibitor, that 
normally phosphorylates RB1, which has to be un-phosphorylated in order to block 
cell-cycle at G1 in normal cells. Adding CDK inhibitor molecules to MM in pre-clinical 
studies has been proven to restore the normal function of p16INK4A, blocking thereby 
MM cell cycle at G1. Future randomised phase III studies with CDK4/6 inhibitors in 
MM carrying relevant CDK4/6, cyclin D1/3 or p16 aberrations will be warranted.
INTRODUCTION
Malignant Mesothelioma (MM) is a rare and 
aggressive disease, for which current treatments have not 
proven very effective. This tumour is particularly common 
in certain geographic regions with historical exposure to 
asbestos and according to the latest data from the Italian 
Registry of Tumours Association, the area of Trieste falls 
into the “high incidence” regions [1]. Based on data from 
the literature, CDKN2A and its protein, tumour suppressor 
p16INK4a, could be an interesting target to pursue for 
medical treatment, as often down-regulated in MM [2]. 
P16INK4a (p16) protein is involved in the regulation of 
the cell cycle machinery, functioning as an inhibitor 
of Cyclin-Dependent Kinases 4 and 6 (CDK4/6). In 
accordance with previous reports, two recent studies found 
that 52.2% and 45% of pleural MMs showed deletions in 
the 9p21 area containing CDKN2A and CDKN2B genes 
[3,4]. Further confirmation of the important role that 
cell cycle dysregulation plays in MM was provided by 
Jennings et al.,: their research showed the presence of 
direct correlation between p16 protein expression levels 
and response to chemotherapy and therefore survival in 
patients with MM [5].   
With the advent of selective anti-CDK 4/6 inhibitors 
such as palbociclib or ribociclib, already approved by 
FDA in the metastatic breast cancer setting, currently at 
different stages of clinical development, dysregulation of 
the cell cycle has become targetable [6]. Cyclin-dependent 
kinases 4 and 6, in a complex with Cyclin D, promote cell-
cycle progression from G1 to S by inactivating the tumour 
suppressor Retinoblastoma-associated protein (RB1) and 
the RB1-like proteins 1 and 2. Cyclin-dependent kinase 
inhibitors, such as p16, also participate in the regulation/
inhibition of CDK 4/6 activity. Loss of p16 and loss of 
RB1 function are generally mutually exclusive in cancer 
cells. When CDKN2A is mutated or hypermetylated, 
inhibition of CDK4/6 by p16 is lost and pro-mitotic 
signals prevail. In the same fashion, when RB1 is mutated, 
cyclin E1 and CDK2 are constitutively activated, with 
the initiation of transcription of pro-mitotic genes. In the 
latter case, cancer cells do not rely on CDK4/6 for the 
transition from G1 to S and therefore are not sensitive 
to CDK4/6 inhibitors. It is clear how both p16 and 
cyclin-dependent kinase 4/6 require a functional RB1 
to exert their cell-cycle regulatory function. Therefore, 
patients selection on the basis of these molecular features 
becomes paramount to the success of future clinical trials 
investigating functional roles of CDK4/6 inhibitors in 
the treatment of MM. Of note, the importance of the p16 
status for the diagnosis of MM was recently confirmed 
by Nabeshima and colleagues [2], while further studies to 
validate its role as a predictor of prognosis and response/
resistance to treatment in patients with MM and other 
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solid tumours are underway [7]. On the basis of the 
role of tumour suppressor gene/protein p16 in the cell-
cycle signalling pathway, and in view of the prevalence 
of mutations found in MM, Frizelle S.P. et al. used a 
p16 peptide (84-103 aa), which exerts minimal CDK-
inhibitory activity, to transduce mesothelioma cells to 
inhibit CDK4\6 and evaluated its therapeutic potential 
in mesothelioma. The p16 peptide (TAT-p16) expression 
over three MM cell lines (H2452, H2052 and H2461) 
induced  RB1 phosphorylation and consequent cell cycle 
arrest at G1, followed by cell death. To corroborate these 
encouraging in vitro results, xenografts with p16-deficient 
mesothelioma cell line H2373 provided in vivo proof 
that induction of TAT-p16 decreases CDK4\6 activity 
resulting in hypophosphorylation of RB1 [8]. Treatment 
of mesothelioma with p16 adenovirus was previously 
demonstrated a useful therapeutic approach in other two 
in vivo studies by the same authors [9,10].
Another proof-of-concept supporting the anti-
tumour activity of p16-mimicking molecules comes 
from a patent filed for novel CDK4/6 inhibitors for 
the treatment of malignant mesothelioma, where the 
authors showed that the new inhibitors are able to stop 
proliferation of three MM cell lines (namely MSTO-211, 
NCI-H2052, NCI-H28) in vitro with cytostatic activity in 
the micromolar range [11]. 
After such promising results, a phase II clinical 
trial has been designed to evaluate the CDK 4/6-inhibitor 
ribociclib in solid tumours, including MM carrying 
relevant CDK4/6, cyclin D1/3 or p16 aberrations 
(NCT02187783).  
Our report would support the need for randomized 
phase III clinical studies specifically designed to test the 
anti-tumour activity of CDK4/6 inhibitors as single agents 
or in combination in MM on the basis of the molecular 
characteristics of this tumour. 
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